Please use this identifier to cite or link to this item:
Title: Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen.
Authors: Kong, Anthony
Rea, Daniel
Ahmed, Samreen
Beck, J Thaddeus
López López, Rafael
Biganzoli, Laura
Armstrong, Anne C
Aglietta, Massimo
Alba, Emilio
Campone, Mario
Hsu Schmitz, Shu-Fang
Lefebvre, Caroline
Akimov, Mikhail
Lee, Soo-Chin
Keywords: AUY922;HER2;HSP90 inhibitor;breast cancer;trastuzumab
metadata.dc.subject.mesh: Adult
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Bayes Theorem
Breast Neoplasms
Cohort Studies
Disease Progression
Dose-Response Relationship, Drug
HSP90 Heat-Shock Proteins
Kaplan-Meier Estimate
Middle Aged
Neoplasm Metastasis
Receptor, ErbB-2
Treatment Outcome
Issue Date: 2016
Abstract: This open-label, multicenter, phase 1B/2 trial assessed AUY922 plus trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer previously treated with chemotherapy and anti-HER2 therapy. This study was composed of a dose-escalation part with AUY922 administered weekly at escalating doses with trastuzumab 2 mg/kg/week (phase 1B), followed by a phase 2 part using the same regimen at recommended phase 2 dose (RP2D). The primary objectives were to determine the maximum tolerated dose (MTD) and/or RP2D (phase 1B), and to evaluate preliminary antitumor activity (phase 2) of AUY922 plus trastuzumab at MTD/RP2D. Forty-five patients were treated with AUY922 plus trastuzumab (4 in phase 1B with AUY922 at 55 mg/m2 and 41 in phase 1B/2 with AUY922 at 70 mg/m2 [7 in phase 1B and 34 in phase 2]). One patient in phase 1B (70 mg/m2) experienced a dose-limiting toxicity (grade 3 diarrhea); the RP2D was weekly AUY922 70 mg/m2 plus trastuzumab. Of the 41 patients in the 70 mg/m2 cohort, the overall response rate (complete or partial responses) was 22.0% and 48.8% patients had stable disease. Study treatment-related adverse events occurred in 97.8% of patients; of these, 31.1% were grade 3 or 4. Forty-one patients (91.1%) reported ocular events (82.3% had grade 1 or 2 events). Two patients (4.4%) had ocular events leading to the permanent discontinuation of study treatment. AUY922 at 70 mg/m2 plus trastuzumab standard therapy is well tolerated and active in patients with HER2-positive metastatic breast cancer who progressed on trastuzumab-based therapy.
metadata.dc.identifier.doi: 10.18632/oncotarget.8974
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC5122341.pdf2,42 MBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons